| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 15.33 | 18.3% | 24.7% |
| Total Income | 15.33 | 18.3% | 24.7% |
| Expenditure | 15.49 | 12.9% | 12.4% |
| PBT | -0.16 | 79.2% | 105.2% |
| Net Profit | -0.16 | 79.2% | 106.0% |
| OPM | 0.79% | 4.68pp | 8.59pp |
| NPM | -1.03% | 4.88pp | 14.13pp |
| EPS | 0.00 | 100.0% | 100.0% |
Solésence Reports Q2 2026 Financial Results
20 Aug 2026 · 20 Aug, 9:51 pm
Summary
Solésence reported second-quarter revenue of $15.3 million, down from $20.4 million in the prior year, impacted by the absence of a major product launch and inventory fill that boosted Q2 2025 results. The company incurred a net loss of $158,000 for the quarter, a reversal from a $3.2 million net income in Q2 2025, with gross margin slightly decreasing to 31%. Despite the year-over-year decline, management expressed confidence in exceeding 2025 full-year revenue, citing $64.9 million in current orders and projecting the strongest second-half performance in the company's history.
Key Highlights
- 1
Solésence reported second-quarter revenue of $15.3 million, a decrease from $20.4 million in the second quarter of 2025, which benefited from a major product launch and inventory fill.
- 2
Gross profit for the second quarter was $4.7 million, down from $6.4 million in the prior year's comparable period.
- 3
The company reported a net loss of $158,000 for the second quarter of 2026, compared to a net income of $3.2 million in the second quarter of 2025.
- 4
Gross margin in the second quarter was 31%, a slight decrease from 32% in the same period of 2025.
- 5
Adjusted EBITDA for the second quarter was $523,000, a significant decrease from $3.7 million in the second quarter of 2025.
- 6
The company expects to outperform 2025 on a full-year revenue basis, with $64.9 million in shipped and on-hand orders as of August 17th, 2026.
- 7
Solésence projects the second half of 2026 to generate approximately $35 million in revenue, marking the strongest second-half performance in the company's history.
Management Comments
Kevin Cureton
In the second quarter, our business focused on operational execution and financial discipline as we continue implementing our Transform and Transcend strategy. By leveraging our intellectual property to enter high-growth markets, and expanding our co-marketing initiatives, we are solidifying our position as a trusted partner to premier brands. Combined with our targeted operational efficiency initiatives, these efforts ensure Solésence remains lean, agile, and structured for long-term value creation. As I mentioned earlier, we want to make sure it’s absolutely clear that we take these inventory valuation changes seriously, and like you, are frustrated and disappointed by issues like this that result from how this business was grown and managed in the past. However, it should not be overlooked that as we exit Q2 and enter Q3, Solesence has gained momentum to achieve double-digit growth, a consistent part of our history. We have also implemented the tools and processes to deliver sustainable profitability commensurate with our expectations as a technology-driven company and those of our investors. More importantly, this accounting matter does not change the commercial reality of our business: our operational momentum is accelerating, our brand partners are growing, and we are entering the strongest second half in Solésence’s history with $64.9 million in shipped and on-hand orders. Thank you Lisa and thank all of you for joining us today. While this accounting issue remains an important matter, our core strengths are unchanged as you just heard through the discussion. Solésence continues to operate as a market leader in a high-growth business, providing a product line with one of the highest growth rates in the category. When paired with our proven operational improvements, these strong fundamentals demonstrate that our underlying momentum continues to build as we execute on the work ahead. To help our stakeholders better understand our long-term trajectory as we continue to advance our Transform and Transcend initiatives, we recently uploaded a strategic vision document to our Investor Relations website, which we encourage you all to review. Looking ahead to the second half of the year, we expect continued progress in our strategy as we demonstrate that Solésence is on the right path to growing our company’s enterprise value at a rate significantly greater than the market and creating long-term value through combining financial and operational excellence with world-leading innovation in skin health. Again, thank you for your continued support, and we look forward to updating you in the next quarter.
Laura Riffner
Before walking through our second-quarter financial performance, I want to address our recent form NT 10-Q filing and provide full clarity on our accounting evaluation. During our quarter-end review, we identified an issue with our historical inventory costing methodology regarding how indirect manufacturing costs were allocated to inventory. Working closely with our advisors, we have completed our evaluation and are implementing the necessary restatement to correct this inventory valuation issue. I want to be clear about what the restatement means for our shareholders. The adjustments relate to the accounting for certain costs within inventory and do not affect the underlying cash generated or used by the business, our day-to-day operations, or our ability to serve our brand partners. The adjustments relate primarily to the accounting for certain costs within inventory and the resulting recognition of those costs in the financial statements. As part of our remediation efforts, we are enhancing our inventory costing processes and related controls, including additional formalized periodic reviews of overhead cost pools, allocation methodologies and burden rates. We are also strengthening the documentation and oversight of these processes to support their consistent application going forward. We will continue implementing these remediation activities. Turning to our operational execution, we continued the disciplined implementation of our transform and transcend strategy in the second quarter, building on our foundational work to drive operational efficiency. For Q2 of 2026, revenue was $15.3 million, compared to $20.4 million in the second quarter of 2025 – which had been a quarter that benefited from a major new product launch and pipeline fill. While Q2 2026 revenue from this product was lower than in Q2 2025, we continue to see gains in both reorders and forecasts for this product line. The drop in revenue for this product line was partially offset by growth with other brand partners in the prestige beauty sector. In Q2 2026, we achieved a 31% gross margin, versus a restated 32% in Q2 2025. This gross margin performance on a 25% lower revenue level as compared to last year is a clear sign of continued improvements in labor efficiency in line with our Transform and Transcend goals, and we are pleased to see that momentum has continued in the second quarter. Second quarter had a loss of $158,000 compared to net income of $3.2 million in the prior year. Adjusted EBITDA for the second quarter was $ 523,000, compared to $3.7 million for the second quarter of last year. The decline in net income and adjusted EBITDA versus the prior year was related to the lower revenue as compared to 2025 and one-time events related to Refy that decreased net income by approximately $938,000, and the ERC payment we received in Q2 2025 that positively increased net income last year by $1.4 million. Looking forward, we can now confidently expect to outperform 2025 on a full-year revenue basis. Underpinning our confidence is that, as of August 17th, our shipped and on-hand orders for 2026, which include orders shipped as well as those we expect to ship this year, totaled $64.9 million, up from $60.0 million in the same period in 2025. We also expect the third quarter to show sequential improvement in both revenue and profitability, and we project that the second half of 2026 will generate approximately $35 million in revenue — marking the strongest second-half performance in the company's history. Overall, while we are disappointed that this issue with our legacy accounting methodology existed, we are fully committed to addressing it and are prepared to do so while maintaining the consistent progress in our first and foundational pillar of Transform and Transcend: operational excellence. While much work remains, we are confident in our ability to continue the positive momentum of Q2. I’ll now turn it back to Kevin.
Informational and educational content only. Not investment advice.